Terguride

Terguride
Clinical data
Trade namesTeluron
Other namesDironyl; Mysalfon; trans-Dihydrolisuride; Transdihydrolisuride; TDHL; SH-406; VUFB-6638; ZK-31224; N,N-Diethyl-N'-[(8α)-6-methylergolin-8-yl]urea
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • 3-[(6aR,9S,10aR)-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinolin-9-yl]-1,1-diethylurea
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.048.732 Edit this at Wikidata
Chemical and physical data
FormulaC20H28N4O
Molar mass340.471 g·mol−1
3D model (JSmol)
SMILES
  • CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
InChI
  • InChI=1S/C20H28N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,11,14,16,18,21H,4-5,9-10,12H2,1-3H3,(H,22,25)/t14-,16+,18+/m0/s1
  • Key:JOAHPSVPXZTVEP-YXJHDRRASA-N
  (verify)

Terguride (INN, JAN), sold under the brand name Teluron, is a serotonin receptor antagonist and dopamine receptor agonist of the ergoline family. It is approved for and used as a prolactin inhibitor in the treatment of hyperprolactinemia (high prolactin levels) in Japan.[1][2] Terguride is taken by mouth.

Pharmacology

Pharmacodynamics

Terguride acts as an agonist of the dopamine D2 receptor and as an antagonist of the serotonin 5-HT2A and 5-HT2B receptors, among other actions.

As an antagonist of the 5-HT2B receptor, terguride is not associated with cardiac valvulopathy.[3]

Activities of terguride at various sites[4][5][6][7]
Site Affinity (Ki [nM]) Efficacy (Emax [%]) Action
D1 28  ?  ?
D2S 0.81 39 Partial agonist
D2L 1.1 0 Silent antagonist
D3 1.0 36 Partial agonist
D4 8.1 0 Silent antagonist
D5 23  ?  ?
5-HT1A 3.5 71 Partial agonist
5-HT1B 257 37 Partial agonist
5-HT1D 16 62 Partial agonist
5-HT2A 4.8 49 Partial agonist
5-HT2B 7.1 0 Silent antagonist
5-HT2C 48 0 Silent antagonist
5-HT7 8–42  ?  ?
α1A 3.5 0 Silent antagonist
α1B 35  ?  ?
α1D 3.9  ?  ?
α2A 0.30 0 Silent antagonist
α2B 0.45 0 Silent antagonist
α2C 0.76 0 Silent antagonist
α2D 1.5  ?  ?
β1 661  ?  ?
β2 20  ?  ?
H1 339  ?  ?
M1 >10,000  ?  ?
Notes: All receptors are human except α2D-adrenergic, which is rat (no human counterpart), and 5-HT7, which was guinea pig.[4][7]

Research

Serotonin stimulates the proliferation of pulmonary artery smooth muscle cells, and induces fibrosis in the wall of pulmonary arteries. Together, this causes vascular remodeling and narrowing of the pulmonary arteries. These changes result in increased vascular resistance and PAH. Due to the potential anti-proliferative and anti-fibrotic activity of terguride, this potential medicine could offer the hope of achieving reversal of pulmonary artery vascular remodeling and attenuation of disease progression.[8] In May 2008, terguride was granted orphan drug status for the treatment of pulmonary arterial hypertension.[9] In May 2010 Pfizer purchased worldwide rights for the drug.[10] However, development was discontinued in 2011.

References

  1. ↑ "List of 5HT3 receptor antagonists (5hydroxytryptamine receptor antagonists)". Archived from the original on 2016-03-03.
  2. ↑ "Terguride - AdisInsight".
  3. ↑ Zajdel P, Bednarski M, Sapa J, Nowak G (April 2015). "Ergotamine and nicergoline - facts and myths". Pharmacol Rep. 67 (2): 360–3. doi:10.1016/j.pharep.2014.10.010. PMID 25712664.
  4. 1 2 Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes". J Pharmacol Exp Ther. 303 (2): 791–804. doi:10.1124/jpet.102.039867. PMID 12388666. S2CID 6200455.
  5. ↑ Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". J Pharmacol Exp Ther. 303 (2): 805–14. doi:10.1124/jpet.102.039875. PMID 12388667. S2CID 35238120.
  6. ↑ Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes". J Pharmacol Exp Ther. 303 (2): 815–22. doi:10.1124/jpet.102.039883. PMID 12388668. S2CID 19260572.
  7. 1 2 "Archived copy". pdsp.unc.edu. Archived from the original on 13 April 2021. Retrieved 15 January 2022.{{cite web}}: CS1 maint: archived copy as title (link)
  8. ↑ Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, et al. (2015). "5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure". BioMed Research International. 2015: 438403. doi:10.1155/2015/438403. PMC 4312574. PMID 25667920.
  9. ↑ Presseportal (Swiss press portal, in German)
  10. ↑ TheDay.com 5/10/2010
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.